Jennifer G. Gaultney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Jennifer G. Gaultney has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Carin A Uyl-De Groot
2 shared publicationsCarin A. Uyl-De Groot
Institute for Medical Technology Assessment/Institute of Health Policy & Management, Erasmus University, Rotterdam, The Netherlands
2 shared publicationsPieter Sonneveld
2 shared publicationsWilliam K Redekop
2 shared publicationsC. A. Uyl-De Groot
Institute for Medical Technology Assessment/Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam
1 shared publicationEnrique Sanhueza
Pontificia Universidad Catolica de Chile, Santiago, Chile
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 18 (1) , 5-7
Efficient Allocation of Novel Agents in Multiple Myeloma: A Work in Progress
This commentary examines key questions regarding the use of novel agents in multiple myeloma, addressed by two articles in this month's issue.
- 1 January 2013
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 18 (1) , 5-7
Open AccessEfficient Allocation of Novel Agents in Multiple Myeloma: A Work in Progress
This commentary examines key questions regarding the use of novel agents in multiple myeloma, addressed by two articles in this month's issue.
- 6 November 2012
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 38 (1) , 41-47
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents
What is known and objective: High costs of novel agents increasingly put pressure on limited healthcare budgets. Demonstration of their real‐world costs and cost‐effectiveness is often required for reimbursement. However, few published economic evaluations of novel agents for multiple myeloma exist. Moreover, existing cost analyses were heavily based on conventionally treated patients. We investigated real‐world health care costs of relapsed/refractory multiple myeloma in Dutch daily practice. Methods: A retrospective medical chart review was conducted for 139 patients treated between January 2001 and May 2009. Total monthly costs attributable to each cost component were described across all regimens and for bortezomib‐, thalidomide‐ and lenalidomide‐based treatment regimens. Results: Mean monthly total costs (€3,981) varied depending on the sequence of therapy (range: €442–€31,318). Significant cost drivers across all regimens included costs of therapy and hospital admissions. The acquisition costs for novel agents in particular accounted for 32% of mean total monthly costs. Prognostic factors associated with increased mean total monthly costs in multivariate regression analysis included low platelet counts (P = 0·01) and worsening performance status (P < 0·001). Mean total monthly costs of bortezomib‐ and lenalidomide‐based regimens were significantly higher than those for thalidomide‐based regimens in second, third and fourth treatment line. What is new and conclusions: Real‐world costs during treatment of relapsed/refractory multiple myeloma vary greatly. Cost drivers include hospital admissions and acquisition costs of novel agents. Costs also vary by prognostic factors and treatment‐related resource use. Future studies assessing the costs of combination therapy consisting of two or more novel agents are encouraged.
- 6 November 2012
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 38 (1) , 41-47
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents
What is known and objective: High costs of novel agents increasingly put pressure on limited healthcare budgets. Demonstration of their real‐world costs and cost‐effectiveness is often required for reimbursement. However, few published economic evaluations of novel agents for multiple myeloma exist. Moreover, existing cost analyses were heavily based on conventionally treated patients. We investigated real‐world health care costs of relapsed/refractory multiple myeloma in Dutch daily practice. Methods: A retrospective medical chart review was conducted for 139 patients treated between January 2001 and May 2009. Total monthly costs attributable to each cost component were described across all regimens and for bortezomib‐, thalidomide‐ and lenalidomide‐based treatment regimens. Results: Mean monthly total costs (€3,981) varied depending on the sequence of therapy (range: €442–€31,318). Significant cost drivers across all regimens included costs of therapy and hospital admissions. The acquisition costs for novel agents in particular accounted for 32% of mean total monthly costs. Prognostic factors associated with increased mean total monthly costs in multivariate regression analysis included low platelet counts (P = 0·01) and worsening performance status (P < 0·001). Mean total monthly costs of bortezomib‐ and lenalidomide‐based regimens were significantly higher than those for thalidomide‐based regimens in second, third and fourth treatment line. What is new and conclusions: Real‐world costs during treatment of relapsed/refractory multiple myeloma vary greatly. Cost drivers include hospital admissions and acquisition costs of novel agents. Costs also vary by prognostic factors and treatment‐related resource use. Future studies assessing the costs of combination therapy consisting of two or more novel agents are encouraged.
- 1 June 2012
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 12 (6) , 839-854
Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value
Recent advances in oncology treatment have improved patient outcomes at the expense of increasing healthcare costs. The indication multiple myeloma is especially characterized by a recent and continuing flood of expensive novel agents. A review encompassing all elements necessary to perform an economic evaluation of novel agents for multiple myeloma was conducted for thalidomide, bortezomib and lenalidomide. Improvements in efficacy have led to a switch from conventional therapy to novel agents as standard therapy. Incremental cost-effectiveness ratios for novel agents alone or in combination with conventional agents were generally regarded to be within acceptable ranges. Conflicting results were reported for the incremental cost-effectiveness of bortezomib versus lenalidomide, as unresolved questions remain regarding their comparative effectiveness. Future economic evaluations will require an assessment of the cost-effectiveness of these agents in terms of sequence within the treatment paradigm and in combination with one another.
- 1 June 2012
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 12 (6) , 839-854
Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value
Recent advances in oncology treatment have improved patient outcomes at the expense of increasing healthcare costs. The indication multiple myeloma is especially characterized by a recent and continuing flood of expensive novel agents. A review encompassing all elements necessary to perform an economic evaluation of novel agents for multiple myeloma was conducted for thalidomide, bortezomib and lenalidomide. Improvements in efficacy have led to a switch from conventional therapy to novel agents as standard therapy. Incremental cost-effectiveness ratios for novel agents alone or in combination with conventional agents were generally regarded to be within acceptable ranges. Conflicting results were reported for the incremental cost-effectiveness of bortezomib versus lenalidomide, as unresolved questions remain regarding their comparative effectiveness. Future economic evaluations will require an assessment of the cost-effectiveness of these agents in terms of sequence within the treatment paradigm and in combination with one another.
- 12 May 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47 (10) , 1458-1467
Critical review of economic evaluations in multiple myeloma: An overview of the economic evidence and quality of the methodology
- 12 May 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47 (10) , 1458-1467
Critical review of economic evaluations in multiple myeloma: An overview of the economic evidence and quality of the methodology
- 30 March 2011
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 12 (3) , 411-421
Application of Cost–Effectiveness Analysis to Demonstrate the Potential value of Companion Diagnostics in Chronic Myeloid Leukemia
A cost-effectiveness analysis was performed to assess the potential value of companion diagnostics in supporting treatment decisions for dasatinib and nilotinib in chronic myeloid leukemia. A decision model was developed, and model inputs were taken from the literature and publicly available sources. The perspective of the healthcare sector in the Netherlands was used. Sensitivity and scenario analyses were performed to assess uncertainty in the results. Companion diagnostics could improve health and reduce costs, despite the estimates being uncertain owing to limited evidence for comparative effectiveness between dasatinib and nilotinib. The results were sensitive to the cost of treatment, utility of progression and progression-free survival. This case demonstrates the use of cost-effectiveness analysis at an early stage of health technology assessment to generate economic evidence for the use of companion diagnostics in treatment decisions and to support decision-making for their development.
- 30 March 2011
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 12 (3) , 411-421
Application of Cost–Effectiveness Analysis to Demonstrate the Potential value of Companion Diagnostics in Chronic Myeloid Leukemia
A cost-effectiveness analysis was performed to assess the potential value of companion diagnostics in supporting treatment decisions for dasatinib and nilotinib in chronic myeloid leukemia. A decision model was developed, and model inputs were taken from the literature and publicly available sources. The perspective of the healthcare sector in the Netherlands was used. Sensitivity and scenario analyses were performed to assess uncertainty in the results. Companion diagnostics could improve health and reduce costs, despite the estimates being uncertain owing to limited evidence for comparative effectiveness between dasatinib and nilotinib. The results were sensitive to the cost of treatment, utility of progression and progression-free survival. This case demonstrates the use of cost-effectiveness analysis at an early stage of health technology assessment to generate economic evidence for the use of companion diagnostics in treatment decisions and to support decision-making for their development.